|
JPS6058915A
(ja)
*
|
1983-09-12 |
1985-04-05 |
Fujisawa Pharmaceut Co Ltd |
薬物含有脂質小胞体製剤
|
|
JPS6072831A
(ja)
*
|
1983-09-29 |
1985-04-24 |
Kao Corp |
ベシクル用組成物
|
|
JPS6072830A
(ja)
*
|
1983-09-29 |
1985-04-24 |
Kao Corp |
ベシクル用組成物
|
|
EP0152379A3
(de)
*
|
1984-02-15 |
1986-10-29 |
Ciba-Geigy Ag |
Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
|
|
DE3515335C2
(de)
*
|
1985-04-27 |
1995-01-26 |
Bayer Ag |
Arzneizubereitung enthaltend Dihydropyridine und Verfahren zu ihrer Herstellung
|
|
IL79114A
(en)
*
|
1985-08-07 |
1990-09-17 |
Allergan Pharma |
Method and composition for making liposomes
|
|
MY101125A
(en)
*
|
1985-12-23 |
1991-07-31 |
Kao Corp |
Gel-like emulsion and o/w emulsions obtained from gel-like emulsion
|
|
FR2597346B1
(fr)
*
|
1986-04-22 |
1989-08-18 |
Oreal |
Procede pour faciliter la formation de niosomes en dispersion dans une phase aqueuse et pour ameliorer leur stabilite et leur taux d'encapsulation, et dispersions correspondantes.
|
|
FR2597367B1
(fr)
*
|
1986-04-22 |
1988-07-15 |
Oreal |
Procede pour faciliter la formation de spherules lipidiques en dispersion dans une phase aqueuse et pour ameliorer leur stabilite et leur taux d'encapsulation, et dispersions correspondantes.
|
|
GB8630273D0
(en)
*
|
1986-12-18 |
1987-01-28 |
Til Medical Ltd |
Pharmaceutical delivery systems
|
|
DK86988A
(da)
*
|
1987-02-25 |
1988-08-26 |
Takeda Chemical Industries Ltd |
Liposompraeparat og anvendelse deraf
|
|
JP2611307B2
(ja)
*
|
1987-02-25 |
1997-05-21 |
武田薬品工業株式会社 |
リポソーム製剤およびその製造法
|
|
EP0525188B1
(en)
*
|
1990-04-18 |
1995-03-01 |
Takeda Chemical Industries, Ltd. |
Liposome composition
|
|
DE4107152C2
(de)
*
|
1991-03-06 |
1994-03-24 |
Gregor Cevc |
Präparate zur nichtinvasiven Verabreichung von Antidiabetica
|
|
JP3765579B2
(ja)
*
|
1990-08-24 |
2006-04-12 |
イーデーエーアー アーゲー |
作用物質投与用超微小滴状調剤
|
|
US6165500A
(en)
*
|
1990-08-24 |
2000-12-26 |
Idea Ag |
Preparation for the application of agents in mini-droplets
|
|
DE4107153A1
(de)
*
|
1991-03-06 |
1992-09-10 |
Gregor Cevc |
Praeparat zur wirkstoffapplikation in kleinsttroepfchenform
|
|
FR2674128A1
(fr)
*
|
1991-03-19 |
1992-09-25 |
Patrinove |
"vecteurs de structure capsulaire" et leurs applications dans le transport de substances ou principes actifs.
|
|
DE4208527A1
(de)
*
|
1992-03-17 |
1993-09-23 |
Max Planck Gesellschaft |
Liposomen mit negativer ueberschussladung
|
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
|
DE4423131A1
(de)
*
|
1994-07-01 |
1996-01-04 |
Bayer Ag |
Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
|
|
US6093697A
(en)
*
|
1994-11-07 |
2000-07-25 |
The University Of Virginia Patent Foundation |
Synthetic insulin mimetic substances
|
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
|
ES2248823T5
(es)
|
1996-10-25 |
2011-11-03 |
Human Genome Sciences, Inc. |
Neutroquina alfa.
|
|
US6156728A
(en)
|
1996-11-01 |
2000-12-05 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
|
US6593290B1
(en)
|
1996-11-01 |
2003-07-15 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
|
JP2002512521A
(ja)
|
1997-05-30 |
2002-04-23 |
ヒューマン ジノーム サイエンシーズ，インコーポレイテッド |
３２個のヒト分泌タンパク質
|
|
US6113947A
(en)
*
|
1997-06-13 |
2000-09-05 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
|
US6663899B2
(en)
|
1997-06-13 |
2003-12-16 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
|
US5906979A
(en)
*
|
1998-01-27 |
1999-05-25 |
Insmed Pharmaceuticals, Inc. |
Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
|
|
CA2318857C
(en)
|
1998-02-04 |
2013-09-24 |
Genentech, Inc. |
Use of heregulin as an epithelial cell growth factor
|
|
NZ525914A
(en)
|
1998-03-10 |
2004-03-26 |
Genentech Inc |
Novel polypeptides and nucleic acids encoding the same
|
|
DE69939374D1
(de)
|
1998-03-17 |
2008-10-02 |
Genentech Inc |
Zu vegf und bmp1 homologe polypeptide
|
|
AU3072799A
(en)
|
1998-03-19 |
1999-10-11 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
|
US6290987B1
(en)
*
|
1998-09-27 |
2001-09-18 |
Generex Pharmaceuticals, Inc. |
Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
|
|
AUPP785098A0
(en)
|
1998-12-21 |
1999-01-21 |
Victor Chang Cardiac Research Institute, The |
Treatment of heart disease
|
|
JP2002533379A
(ja)
|
1998-12-23 |
2002-10-08 |
イデア アクチェンゲゼルシャフト |
生体内における局所的に非侵襲性である用途のための改善された製剤
|
|
ATE216875T1
(de)
|
1999-01-27 |
2002-05-15 |
Idea Ag |
Nichtinvasive impfung durch die haut
|
|
PT1031347E
(pt)
|
1999-01-27 |
2002-09-30 |
Idea Ag |
Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
|
|
EP2357192A1
(en)
|
1999-02-26 |
2011-08-17 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
|
US6635249B1
(en)
|
1999-04-23 |
2003-10-21 |
Cenes Pharmaceuticals, Inc. |
Methods for treating congestive heart failure
|
|
WO2001001962A1
(en)
|
1999-07-05 |
2001-01-11 |
Idea Ag. |
A method for the improvement of transport across adaptable semi-permeable barriers
|
|
EP2206720A1
(en)
|
2000-04-12 |
2010-07-14 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
CA2413160A1
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
|
CA2648048A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
|
EP2275549A1
(en)
|
2000-06-23 |
2011-01-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
|
AUPR546801A0
(en)
|
2001-06-05 |
2001-06-28 |
Commonwealth Scientific And Industrial Research Organisation |
Recombinant antibodies
|
|
EP1572887A4
(en)
|
2001-08-24 |
2008-12-24 |
Neuren Pharmaceuticals Ltd |
NERVE REGENERATING PEPTIDE AND METHOD FOR THEIR USE IN THE TREATMENT OF A BRAIN DAMAGE
|
|
PL368972A1
(en)
|
2001-08-29 |
2005-04-04 |
Genentech, Inc. |
Bv8 nucleic acids and polypeptides with mitogenic activity
|
|
KR100989647B1
(ko)
|
2001-09-24 |
2010-10-26 |
오레곤 헬스 앤드 사이언스 유니버시티 |
식습관의 변화
|
|
CA2462883A1
(en)
|
2001-10-12 |
2003-04-17 |
Schering Corporation |
Use of bispecific antibodies to regulate immune responses
|
|
EP2261250B1
(en)
|
2001-12-21 |
2015-07-01 |
Human Genome Sciences, Inc. |
GCSF-Albumin fusion proteins
|
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
|
EP1474163A2
(en)
|
2002-01-10 |
2004-11-10 |
Imperial College Innovations Limited |
Modification of feeding behavior
|
|
WO2003099320A1
(en)
|
2002-05-24 |
2003-12-04 |
Zensun (Shanghai) Sci-Tech.Ltd |
Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
|
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
US20040105881A1
(en)
|
2002-10-11 |
2004-06-03 |
Gregor Cevc |
Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
|
|
DE60333228D1
(de)
|
2002-12-02 |
2010-08-12 |
Amgen Fremont Inc |
Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
|
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
|
JP4912144B2
(ja)
|
2003-03-12 |
2012-04-11 |
ジェネンテック， インコーポレイテッド |
造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
|
|
DK1613750T3
(da)
|
2003-03-19 |
2016-01-18 |
Amgen Fremont Inc |
Antistoffer mod t-celle-immunglobulindomæne og mucindo-mæne 1 (tim-1)-antigen og anvendelser deraf
|
|
US7375076B2
(en)
|
2003-05-20 |
2008-05-20 |
The Regents Of The University Of Michigan |
Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
|
|
US7291590B2
(en)
|
2003-06-12 |
2007-11-06 |
Queen's University At Kingston |
Compositions and methods for treating atherosclerosis
|
|
CN102558352A
(zh)
|
2003-06-27 |
2012-07-11 |
艾默根佛蒙特有限公司 |
针对表皮生长因子受体的缺失突变体的抗体及其使用
|
|
DK2274978T3
(da)
|
2003-09-12 |
2015-06-15 |
Ipsen Biopharmaceuticals Inc |
Fremgangsmåder til behandling af en insulin-lignende vækstfaktor-I(IGF-I)-mangel
|
|
EP2327724A3
(en)
|
2004-02-02 |
2011-07-27 |
Ambrx, Inc. |
Modified human growth hormone polypeptides and their uses
|
|
US7807176B2
(en)
|
2004-03-19 |
2010-10-05 |
Genomidea, Inc. |
Polypeptide promoting vascular endothelial cell growth
|
|
WO2005092926A2
(en)
|
2004-03-19 |
2005-10-06 |
Amgen Inc. |
Reducing the risk of human and anti-human antibodies through v gene manipulation
|
|
EP1598428A1
(en)
|
2004-05-18 |
2005-11-23 |
Georg Dewald |
Methods and kits to detect Hereditary angioedema type III
|
|
KR101699142B1
(ko)
|
2004-06-18 |
2017-01-23 |
암브룩스, 인코포레이티드 |
신규 항원-결합 폴리펩티드 및 이의 용도
|
|
JP2008507280A
(ja)
|
2004-07-21 |
2008-03-13 |
アンブレツクス・インコーポレイテツド |
非天然コードアミノ酸を用いた生合成ポリペプチド
|
|
CA2577442A1
(en)
|
2004-08-17 |
2006-03-02 |
The Johns Hopkins University |
Pde5 inhibitor compositions and methods for treating cardiac indications
|
|
CA2583061C
(en)
|
2004-10-06 |
2015-02-17 |
Kwang Guan Tay |
Antibody production method
|
|
JP2008520684A
(ja)
|
2004-11-17 |
2008-06-19 |
アブジェニックス・インコーポレーテッド |
Ｉｌ−１３に対する完全ヒトモノクローナル抗体
|
|
ATE504602T1
(de)
|
2004-12-20 |
2011-04-15 |
Amgen Fremont Inc |
Für humane matriptase spezifische bindungsproteine
|
|
BRPI0519596B1
(pt)
|
2004-12-21 |
2022-01-18 |
Astrazeneca Ab |
Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado
|
|
EP1828224B1
(en)
|
2004-12-22 |
2016-04-06 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
JP2008525473A
(ja)
|
2004-12-22 |
2008-07-17 |
アンブレツクス・インコーポレイテツド |
修飾されたヒト成長ホルモン
|
|
EP1851245B1
(en)
|
2005-01-26 |
2012-10-10 |
Amgen Fremont Inc. |
Antibodies against interleukin-1 beta
|
|
DK1899378T3
(da)
|
2005-06-21 |
2010-02-01 |
Xoma Technology Ltd |
IL-1 beta-bindende antistoffer og fragmenter deraf
|
|
AU2006272497B2
(en)
|
2005-07-27 |
2012-07-19 |
University Of Florida Research Foundation, Inc. |
Small compounds that correct protein misfolding and uses thereof
|
|
EA015860B1
(ru)
|
2005-10-13 |
2011-12-30 |
Хьюман Дженом Сайенсиз, Инк. |
Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
|
|
EP2548583A3
(en)
|
2005-11-10 |
2013-02-27 |
Curagen Corporation |
Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
|
|
EP1951890A4
(en)
|
2005-11-16 |
2009-06-24 |
Ambrx Inc |
PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS
|
|
US20070213264A1
(en)
|
2005-12-02 |
2007-09-13 |
Mingdong Zhou |
Neuregulin variants and methods of screening and using thereof
|
|
WO2008024128A2
(en)
|
2005-12-05 |
2008-02-28 |
Simon Delagrave |
Loop-variant pdz domains as biotherapeutics, diagnostics and research reagents
|
|
ES2385054T3
(es)
|
2005-12-13 |
2012-07-17 |
Medimmune Limited |
Proteínas de unión específicas para factores de crecimiento de tipo insulina y usos de las mismas
|
|
DE602005023550D1
(de)
|
2005-12-14 |
2010-10-21 |
Licentia Ltd |
Verwendungen eines neurotrophischen Faktors
|
|
CA2633211A1
(en)
|
2005-12-15 |
2007-06-21 |
Astrazeneca Ab |
Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
|
|
NZ568809A
(en)
|
2005-12-22 |
2011-08-26 |
Genentech Inc |
Recovering and purification of VEGF proteins from prokaryotic cells using polyanionic agents
|
|
JP5738516B2
(ja)
|
2005-12-30 |
2015-06-24 |
ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド |
心機能改善のためのニューレグリンの徐放
|
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
|
JP5140824B2
(ja)
*
|
2006-04-19 |
2013-02-13 |
国立大学法人 東京大学 |
リゾホスファチジルスレオニンおよびその誘導体
|
|
US8124743B2
(en)
|
2006-06-01 |
2012-02-28 |
President And Fellows Of Harvard College |
Purification of a bivalently active antibody using a non-chromatographic method
|
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
|
JP5256199B2
(ja)
|
2006-08-07 |
2013-08-07 |
テヴァ バイオファーマシューティカルズ ユーエスエー，インコーポレーティッド |
アルブミン−インスリン融合タンパク質
|
|
CN106008699A
(zh)
|
2006-09-08 |
2016-10-12 |
Ambrx公司 |
经修饰的人类血浆多肽或Fc骨架和其用途
|
|
ES2437110T3
(es)
|
2006-11-14 |
2014-01-08 |
Genentech, Inc. |
Moduladores de la regeneración neuronal
|
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
|
CA2673592C
(en)
|
2006-12-20 |
2014-03-25 |
Xoma Technology Ltd. |
Methods for the treatment of il-1.beta. related diseases
|
|
CA2682147C
(en)
|
2007-03-30 |
2017-08-08 |
Ambrx, Inc. |
Modified fgf-21 polypeptides and their uses
|
|
JP5443979B2
(ja)
|
2007-05-11 |
2014-03-19 |
備前化成株式会社 |
新規のロイコトリエン受容体アンタゴニスト
|
|
CN101932602B
(zh)
|
2007-06-27 |
2017-05-24 |
新加坡国立大学 |
用于Artemin及相关配体的多肽和多核苷酸，及其使用方法
|
|
US20090156488A1
(en)
|
2007-09-12 |
2009-06-18 |
Zensun (Shanghai) Science & Technology Limited |
Use of neuregulin for organ preservation
|
|
EP2040075A1
(en)
|
2007-09-24 |
2009-03-25 |
Julius-Maximilians-Universität Würzburg |
Compounds and markers for surface-enhanced raman scattering
|
|
TW200927761A
(en)
|
2007-09-26 |
2009-07-01 |
U3 Pharma Ag |
Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
|
|
MX2010005317A
(es)
|
2007-11-20 |
2010-06-02 |
Ambrx Inc |
Polipeptidos de insulina modificados y sus usos.
|
|
US8637029B2
(en)
|
2007-12-20 |
2014-01-28 |
Xoma Technology Ltd. |
Methods for the treatment of gout
|
|
NZ586947A
(en)
|
2008-02-08 |
2012-11-30 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
|
FI20080326A0
(fi)
|
2008-04-30 |
2008-04-30 |
Licentia Oy |
Neurotroofinen tekijä MANF ja sen käytöt
|
|
US20110293520A1
(en)
|
2008-06-09 |
2011-12-01 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
|
|
PT2318029T
(pt)
|
2008-07-23 |
2018-01-10 |
Ambrx Inc |
Polipéptidos de g-csf bovino modificados e suas utilizações
|
|
EP3629022A1
(en)
|
2008-07-25 |
2020-04-01 |
Richard W. Wagner |
Protein screening methods
|
|
JP5859307B2
(ja)
|
2008-09-10 |
2016-02-10 |
ジェネンテック， インコーポレイテッド |
眼の血管新生を阻害する方法
|
|
RU2581962C2
(ru)
|
2008-09-19 |
2016-04-20 |
Медиммун Ллк |
Нацеленные средства связывания, направленные на dll4, и их применение
|
|
MX2011003272A
(es)
|
2008-09-26 |
2011-04-28 |
Ambrx Inc |
Polipeptidos de eritropoyetina animal modificados y sus usos.
|
|
PE20110480A1
(es)
|
2008-09-26 |
2011-07-01 |
Ambrx Inc |
Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales
|
|
WO2010048446A2
(en)
|
2008-10-22 |
2010-04-29 |
Genentech, Inc. |
Modulation of axon degeneration
|
|
WO2010070136A2
(en)
|
2008-12-19 |
2010-06-24 |
Centre de Recherche Public de la Santé |
Novel caviidae allergens and uses thereof
|
|
EP2367564A1
(en)
|
2008-12-22 |
2011-09-28 |
Universität Regensburg |
Norrin in the treatment of diseases associated with an increased tgf-beta activity
|
|
WO2010072740A2
(en)
|
2008-12-23 |
2010-07-01 |
Astrazeneca Ab |
TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
|
|
WO2010085086A2
(ko)
|
2009-01-20 |
2010-07-29 |
한올바이오파마 주식회사 |
변형된 인간 트롬보포이에틴 폴리펩타이드 절편 및 그의 제조방법
|
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
|
KR20110118811A
(ko)
|
2009-02-13 |
2011-11-01 |
노파르티스 아게 |
비-리보좀 펩티드 합성효소를 코딩하는 생합성 클러스터의 핵산 분자 및 그의 용도
|
|
EP2260857A1
(en)
|
2009-06-11 |
2010-12-15 |
Alfact Innovation |
Novel applications of HIP/PAP or derivatives thereof
|
|
IN2012DN00352A
(da)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
|
EP2305810A1
(en)
|
2009-10-02 |
2011-04-06 |
Technische Universität München |
miRNAs in the treatment of fibrosis
|
|
US20120282266A1
(en)
|
2009-10-16 |
2012-11-08 |
Auckland Uniservices Limited |
Anti-neoplastic uses of artemin antagonists
|
|
CA2778483A1
(en)
|
2009-10-22 |
2011-04-28 |
Genentech, Inc. |
Modulation of axon degeneration
|
|
WO2011056650A2
(en)
|
2009-10-27 |
2011-05-12 |
Michael Zasloff |
Methods and compositions for treating and preventing viral infections
|
|
NZ628923A
(en)
|
2009-11-24 |
2016-02-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
|
WO2011066260A2
(en)
|
2009-11-25 |
2011-06-03 |
Michael Zasloff |
Formulations comprising aminosterols
|
|
NZ600361A
(en)
|
2009-12-21 |
2014-06-27 |
Ambrx Inc |
Modified bovine somatotropin polypeptides and their uses
|
|
JP2013515081A
(ja)
|
2009-12-21 |
2013-05-02 |
アンブルックス，インコーポレイテッド |
修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
|
|
US20130053438A1
(en)
|
2010-01-19 |
2013-02-28 |
Universitat Innsbruck |
Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
|
|
JP6046493B2
(ja)
|
2010-01-27 |
2016-12-14 |
チルドレンズ メディカル センター コーポレーション |
プロミニン−１の血管新生促進フラグメントおよびその使用
|
|
EP2561068A1
(en)
|
2010-04-19 |
2013-02-27 |
Medizinische Universität Innsbruck |
Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
|
|
EP3181692A1
(en)
|
2010-05-07 |
2017-06-21 |
Centre National De La Recherche Scientifique |
Ucp1 (thermogenin) - inducing agents for use in the treatment of a disorder of the energy homeostasis
|
|
ES2486321T3
(es)
|
2010-06-18 |
2014-08-18 |
Xiberscience Gmbh |
Péptidos como agentes activos para estabilizar barreras biológicas
|
|
MA34521B1
(fr)
|
2010-08-17 |
2013-09-02 |
Ambrx Inc |
Polypeptides de relaxine modifiés et leurs utilisations
|
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
|
AU2012209466C1
(en)
|
2011-01-27 |
2016-06-23 |
Neuren Pharmaceuticals Limited |
Treatment of Autism Spectrum Disorders using Glycyl-L-2-Methylprolyl-L-Glutamic Acid
|
|
CN103533928A
(zh)
|
2011-03-10 |
2014-01-22 |
霍夫曼-拉罗奇有限公司 |
对具有改变的血管屏障功能的病症的治疗
|
|
EA032666B1
(ru)
|
2011-06-14 |
2019-06-28 |
Бикам Фармасьютикалз, Инк. |
Опсинсвязывающие лиганды и способы их применения
|
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
|
US9745288B2
(en)
|
2011-08-16 |
2017-08-29 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
|
US9328386B2
(en)
|
2011-08-16 |
2016-05-03 |
Evotec (München) Gmbh |
Markers for susceptibility to an inhibitor of an Src-family kinase
|
|
WO2013053076A1
(en)
|
2011-10-10 |
2013-04-18 |
Zensun （Shanghai）Science & Technology Limited |
Compositions and methods for treating heart failure
|
|
HK1202252A1
(en)
|
2011-11-16 |
2015-09-25 |
Amgen Inc. |
Methods of treating epidermal growth factor deletion mutant viii related disorders
|
|
AU2012346214B2
(en)
|
2011-11-30 |
2017-09-14 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
|
EP2601941A1
(en)
|
2011-12-06 |
2013-06-12 |
Ludwig-Maximilians-Universität München |
Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
|
|
US9376715B2
(en)
|
2011-12-09 |
2016-06-28 |
Roche Molecular Systems, Inc |
Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
|
|
US20150017157A1
(en)
|
2011-12-19 |
2015-01-15 |
Xoma (Us) Llc |
Methods for treating acne
|
|
EP3663314A1
(en)
|
2012-01-09 |
2020-06-10 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
|
US10774132B2
(en)
|
2012-01-09 |
2020-09-15 |
The Scripps Research Instittue |
Ultralong complementarity determining regions and uses thereof
|
|
EP2626066A1
(en)
|
2012-02-10 |
2013-08-14 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
|
|
EP2666775A1
(en)
|
2012-05-21 |
2013-11-27 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
|
CN104718188B
(zh)
|
2012-05-22 |
2018-08-21 |
基因泰克公司 |
N-取代的苯甲酰胺类及其在治疗疼痛中的用途
|
|
EP2852584B1
(en)
|
2012-05-22 |
2018-02-28 |
F. Hoffmann-La Roche AG |
Substituted dipyridylamines and uses thereof
|
|
WO2014006063A2
(en)
|
2012-07-02 |
2014-01-09 |
Medizinische Universität Wien |
Complement split product c4d for the treatment of inflammatory conditions
|
|
KR101663436B1
(ko)
|
2012-07-06 |
2016-10-06 |
제넨테크, 인크. |
N-치환된 벤즈아미드 및 이의 사용 방법
|
|
EP2687225A1
(en)
|
2012-07-19 |
2014-01-22 |
Alfact Innovation |
HIP/PAP protein and derivatives thereof for use in treating cancer
|
|
EP2695950A1
(en)
|
2012-08-10 |
2014-02-12 |
Blackfield AG |
Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
|
|
US9119858B2
(en)
|
2012-08-21 |
2015-09-01 |
Genesys Research Institute, Inc. |
Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
|
|
CN104684899B
(zh)
|
2012-09-27 |
2017-07-04 |
霍夫曼-拉罗奇有限公司 |
取代的磺酰胺化合物
|
|
KR102291355B1
(ko)
|
2012-11-30 |
2021-08-19 |
에프. 호프만-라 로슈 아게 |
Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
|
|
CA2896187A1
(en)
|
2013-01-18 |
2014-07-24 |
F. Hoffmann-La Roche Ag |
3-substituted pyrazoles and use as dlk inhibitors
|
|
RU2015143906A
(ru)
|
2013-03-14 |
2017-04-18 |
Дженентек, Инк. |
Замещенные триазолопиридины и способы их применения
|
|
PH12019502378A1
(en)
|
2013-05-01 |
2022-05-11 |
Hoffmann La Roche |
Biheteroaryl compounds and uses thereof
|
|
CA2907912A1
(en)
|
2013-05-01 |
2014-11-06 |
F. Hoffmann-La Roche Ag |
C-linked heterocycloalkyl substituted pyrimidines and their uses
|
|
WO2014187881A1
(en)
|
2013-05-21 |
2014-11-27 |
Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. |
Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
|
|
RU2015154737A
(ru)
|
2013-05-22 |
2017-06-27 |
Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. |
Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности
|
|
WO2014191630A2
(en)
|
2013-05-28 |
2014-12-04 |
Helsingin Yliopisto |
Non-human animal model encoding a non-functional manf gene
|
|
WO2014193800A2
(en)
|
2013-05-28 |
2014-12-04 |
The Johns Hopkins University |
Aptamers for the treatment of sickle cell disease
|
|
EP2810648A1
(en)
|
2013-06-04 |
2014-12-10 |
Daniel Rauh |
Targeting domain-domain interaction for the identification of kinase modulators
|
|
EP2835135A3
(en)
|
2013-06-19 |
2015-06-24 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin |
Means and methods for treating pseudomonas infection
|
|
WO2014207213A1
(en)
|
2013-06-28 |
2014-12-31 |
Medizinische Universität Innsbruck |
Novel inhibitors of protein kinase c epsilon signaling
|
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
|
AU2014290361B2
(en)
|
2013-07-18 |
2019-04-18 |
Taurus Biosciences, Llc |
Humanized antibodies with ultralong complementarity determining regions
|
|
WO2015022326A1
(en)
|
2013-08-12 |
2015-02-19 |
Xiber Science Gmbh |
Peptides as active agents for treating primary graft dysfunction
|
|
CN105792851B
(zh)
|
2013-09-13 |
2023-10-10 |
斯克利普斯研究所 |
修饰的治疗剂及其组合物
|
|
PT2808338E
(pt)
|
2013-09-16 |
2016-06-15 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Calreticulina mutante para o diagnóstico de malignidades mieloides
|
|
ES2713323T3
(es)
|
2013-10-11 |
2019-05-21 |
Hoffmann La Roche |
Compuestos de sulfonamida heterocíclicos sustituidos útiles como moduladores de trpa1
|
|
KR102339240B1
(ko)
|
2013-10-15 |
2021-12-15 |
더 스크립스 리서치 인스티튜트 |
펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
|
|
EP3057991B8
(en)
|
2013-10-15 |
2019-09-04 |
The Scripps Research Institute |
Chimeric antigen receptor t cell switches and uses thereof
|
|
AU2014364589B2
(en)
|
2013-12-18 |
2020-02-27 |
The California Institute For Biomedical Research |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
|
MX2016008110A
(es)
|
2013-12-20 |
2016-08-19 |
Hoffmann La Roche |
Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
|
|
EP3104873B1
(en)
|
2014-02-13 |
2019-09-04 |
Technische Universität München |
Fgf-8 for use in treating diseases or disorders of energy homeostasis
|
|
JP2017508798A
(ja)
|
2014-03-07 |
2017-03-30 |
ザ ジョンズ ホプキンス ユニバーシティ |
ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤
|
|
WO2015153639A1
(en)
|
2014-03-31 |
2015-10-08 |
The Johns Hopkins University |
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies
|
|
US10507227B2
(en)
|
2014-04-15 |
2019-12-17 |
The Hospital For Sick Children |
Cationic antimicrobial peptides
|
|
WO2015173398A1
(en)
|
2014-05-15 |
2015-11-19 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Antagonists of slc38a9 and their use in therapy
|
|
EP2947460A1
(en)
|
2014-05-22 |
2015-11-25 |
Medizinische Universität Wien |
Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
|
|
US11357748B2
(en)
|
2014-05-30 |
2022-06-14 |
The Johns Hopkins University |
Methods for treating mendelian disorders of the epigenetic machinery
|
|
JP2017525677A
(ja)
|
2014-07-07 |
2017-09-07 |
ジェネンテック， インコーポレイテッド |
治療用化合物及びその使用方法
|
|
EP3177279B1
(en)
|
2014-08-09 |
2025-06-04 |
Avanti Polar Lipids, LLC |
Oral composition for delivery of drugs and other substances
|
|
CN107109410B
(zh)
|
2014-08-22 |
2021-11-02 |
奥克兰联合服务有限公司 |
通道调节剂
|
|
EP3000814A1
(en)
|
2014-09-26 |
2016-03-30 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
|
SMT202100388T1
(it)
|
2014-10-24 |
2021-09-14 |
Bristol Myers Squibb Co |
Polipeptidi fgf-21 modificati e loro usi
|
|
WO2016079321A1
(en)
|
2014-11-20 |
2016-05-26 |
Cemm Forschungszentrum Für Molekulare Medizin Gmbh |
Antagonists of setdb2 for use in the therapy of infectious diseases
|
|
WO2016135138A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
|
|
WO2016135140A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
|
|
WO2016135139A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
|
WO2016135137A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
|
KR20170138410A
(ko)
|
2015-02-23 |
2017-12-15 |
시걸 테라퓨틱스 에스에이에스 |
비-천연 세마포린 3 및 이의 의학적 용도
|
|
WO2016142310A1
(en)
|
2015-03-09 |
2016-09-15 |
F. Hoffmann-La Roche Ag |
Tricyclic dlk inhibitors and uses thereof
|
|
WO2016154621A1
(en)
|
2015-03-26 |
2016-09-29 |
The California Institute For Biomedical Research |
SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
|
|
WO2016168773A2
(en)
|
2015-04-15 |
2016-10-20 |
The California Institute For Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
|
WO2016170102A1
(en)
|
2015-04-22 |
2016-10-27 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
|
|
US20180146703A1
(en)
*
|
2015-05-15 |
2018-05-31 |
The Johns Hopkins University |
Novel fluoride prenatal dietary supplement
|
|
HK1252567A1
(zh)
|
2015-05-22 |
2019-05-31 |
基因泰克公司 |
被取代的苯甲酰胺和其使用方法
|
|
WO2016205488A1
(en)
|
2015-06-17 |
2016-12-22 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
|
WO2017007955A1
(en)
|
2015-07-07 |
2017-01-12 |
The Research Foundation For The State University Of New York |
Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
|
|
US10842763B2
(en)
|
2015-07-31 |
2020-11-24 |
The Johns Hopkins University |
Methods for cancer and immunotherapy using prodrugs of glutamine analogs
|
|
AU2016302940B2
(en)
|
2015-07-31 |
2021-02-04 |
The Johns Hopkins University |
Prodrugs of glutamine analogs
|
|
CA2994165A1
(en)
|
2015-07-31 |
2017-02-09 |
The Johns Hopkins University |
Methods for cancer and immunotherapy using glutamine analogues, including don
|
|
EP3328374A4
(en)
|
2015-07-31 |
2019-03-13 |
The Johns Hopkins University |
GLUTAMINANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITES
|
|
JP2018526371A
(ja)
|
2015-08-27 |
2018-09-13 |
ジェネンテック， インコーポレイテッド |
治療化合物及びその使用方法
|
|
CN108834415B
(zh)
|
2015-11-13 |
2021-12-24 |
多曼治疗学公司 |
作为ii组代谢型谷氨酸受体的别构调节剂的取代的三环1,4-苯并二氮杂䓬酮衍生物
|
|
EP3380466A1
(en)
|
2015-11-25 |
2018-10-03 |
Genentech, Inc. |
Substituted benzamides useful as sodium channel blockers
|
|
MX377528B
(es)
|
2015-12-09 |
2025-03-10 |
Univ Wien Med |
Compuestos de platino funcionalizados con monomaleimida para la terapia del cáncer.
|
|
AU2017207867A1
(en)
|
2016-01-15 |
2018-08-09 |
Universität Hamburg |
Flavonoide-type compounds bearing an O-rhamnosyl residue
|
|
MX2018009870A
(es)
|
2016-02-15 |
2018-11-29 |
Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh |
Inhibidores de taf1 para la terapia del cancer.
|
|
EP3216458A1
(en)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modified vascular endothelial growth factor a (vegf-a) and its medical use
|
|
EP3436432B1
(en)
|
2016-03-30 |
2021-01-27 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
|
ES2957548T3
(es)
|
2016-04-15 |
2024-01-22 |
Univ Oxford Innovation Ltd |
Moduladores del receptor de adenosina para el tratamiento de los trastornos del ritmo circadiano
|
|
EP3984540A3
(en)
|
2016-06-28 |
2022-07-06 |
Aequor, Inc. |
Antimicrobial compounds and methods of use
|
|
WO2018015410A1
(en)
|
2016-07-20 |
2018-01-25 |
F. Hoffmann-La Roche Ag |
Bicyclic proline compounds
|
|
JP6975515B2
(ja)
|
2016-07-20 |
2021-12-01 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Ｔｒｐａ１モデュレーターとしてのスルホニルシクロアルキルカルボキサミド化合物
|
|
WO2018024654A1
(en)
|
2016-08-02 |
2018-02-08 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Heterocyclic diamidines
|
|
JP7071959B2
(ja)
|
2016-08-12 |
2022-05-19 |
エフ．ホフマン－ラ ロシュ アーゲー |
スルホニルピリジルｔｒｐ阻害剤
|
|
US11292783B2
(en)
|
2016-09-16 |
2022-04-05 |
Research Triangle Institute |
Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists
|
|
EP3526219B1
(en)
|
2016-10-17 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Bicyclic pyridone lactams and methods of use thereof
|
|
CN110267982B
(zh)
|
2016-10-19 |
2024-02-23 |
斯克利普斯研究所 |
具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
|
|
WO2018087401A2
(en)
|
2016-11-14 |
2018-05-17 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Combination of a brd4 inhibitor and an antifolate for the therapy of cancer
|
|
CN110225911B
(zh)
|
2016-11-28 |
2022-04-05 |
豪夫迈·罗氏有限公司 |
噁二唑酮瞬时受体电位通道抑制剂
|
|
MA46937A
(fr)
|
2016-11-30 |
2019-10-09 |
Oncotyrol Center For Personalized Cancer Medicine Gmbh |
3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones en tant qu'inhibiteurs de kinases dépendantes des cyclines
|
|
US11071721B2
(en)
|
2016-12-02 |
2021-07-27 |
Genentech, Inc. |
Bicyclic amide compounds and methods of use thereof
|
|
US11072607B2
(en)
|
2016-12-16 |
2021-07-27 |
Genentech, Inc. |
Inhibitors of RIP1 kinase and methods of use thereof
|
|
CN110637027B
(zh)
|
2017-02-08 |
2024-08-30 |
百时美施贵宝公司 |
包含药代动力学增强子的修饰的松弛素多肽及其用途
|
|
WO2018162607A1
(en)
|
2017-03-07 |
2018-09-13 |
F. Hoffmann-La Roche Ag |
Oxadiazole transient receptor potential channel inhibitors
|
|
JP2020511511A
(ja)
|
2017-03-24 |
2020-04-16 |
ジェネンテック， インコーポレイテッド |
ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
|
|
CN110769830A
(zh)
|
2017-05-12 |
2020-02-07 |
马瓦隆治疗有限公司 |
作为ii组代谢型谷氨酸受体的别构调节剂的取代的杂环化合物
|
|
JP7283699B2
(ja)
|
2017-05-12 |
2023-05-30 |
マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ |
黒色腫の治療または予防において使用するためのフェニル－ヘテロ環－フェニル誘導体
|
|
US11098058B2
(en)
|
2017-07-14 |
2021-08-24 |
Genentech, Inc. |
Bicyclic ketone compounds and methods of use thereof
|
|
CN111372599A
(zh)
|
2017-07-19 |
2020-07-03 |
奥克兰联合服务有限公司 |
细胞因子调节
|
|
PE20211246A1
(es)
|
2017-10-11 |
2021-07-13 |
Hoffmann La Roche |
Compuestos biciclicos para su uso como inhibidores de rip1 quinasa
|
|
US11066438B2
(en)
|
2017-10-30 |
2021-07-20 |
Enterin, Inc. |
Squalamine solid forms and methods of making the same
|
|
SG11202002877RA
(en)
|
2017-10-31 |
2020-04-29 |
Hoffmann La Roche |
Bicyclic sulfones and sulfoxides and methods of use thereof
|
|
EP3720850A1
(en)
|
2017-12-05 |
2020-10-14 |
ETH Zurich |
New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
|
|
WO2019164778A1
(en)
|
2018-02-20 |
2019-08-29 |
Genentech, Inc. |
Process for preparing 1-arylsulfonyl-pyrrolidine-2-carboxamide transient receptor potential channel antagonist compounds and crystalline forms thereof
|
|
AR114263A1
(es)
|
2018-02-26 |
2020-08-12 |
Genentech Inc |
Compuestos terapéuticos y métodos para utilizarlos
|
|
US10710994B2
(en)
|
2018-03-19 |
2020-07-14 |
Genentech, Inc. |
Oxadiazole transient receptor potential channel inhibitors
|
|
US10947251B2
(en)
|
2018-03-30 |
2021-03-16 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
|
JP7611812B2
(ja)
|
2018-04-06 |
2025-01-10 |
ツィレンティン アーゲー |
多汗症を治療するためのブメタニド誘導体
|
|
US20210163406A1
(en)
|
2018-04-06 |
2021-06-03 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
|
|
WO2019204537A1
(en)
|
2018-04-20 |
2019-10-24 |
Genentech, Inc. |
N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
|
|
WO2019207051A1
(en)
|
2018-04-25 |
2019-10-31 |
Università Degli Studi Di Torino |
Medical use of combinations of non-natural semaphorins 3 and antimetabolites
|
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
|
CA3103265A1
(en)
|
2018-06-12 |
2019-12-19 |
Angiex, Inc. |
Antibody-oligonucleotide conjugates
|
|
WO2020047176A1
(en)
|
2018-08-28 |
2020-03-05 |
Ambrx, Inc. |
Anti-cd3 antibody folate bioconjugates and their uses
|
|
WO2020051099A1
(en)
|
2018-09-03 |
2020-03-12 |
Genentech, Inc. |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
|
HRP20240016T1
(hr)
|
2018-09-11 |
2024-03-29 |
Ambrx, Inc. |
Konjugati polipeptida interleukina-2 i njihove uporabe
|
|
WO2020053808A1
(en)
|
2018-09-12 |
2020-03-19 |
Georg Dewald |
Method of diagnosing vasoregulatory disorders
|
|
WO2020082057A1
(en)
|
2018-10-19 |
2020-04-23 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
|
AU2019407650B2
(en)
|
2018-12-17 |
2022-10-27 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
|
|
CN113302193A
(zh)
|
2019-01-11 |
2021-08-24 |
豪夫迈·罗氏有限公司 |
双环吡咯并三唑酮化合物及其使用方法
|
|
JP7695885B2
(ja)
|
2019-02-12 |
2025-06-19 |
アンブルックス，インコーポレイテッド |
抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
|
|
WO2020198136A1
(en)
|
2019-03-22 |
2020-10-01 |
New York Medical College |
Use of rifaximin on circulating aged neutrophils in sickle cell disease
|
|
EP4004041A1
(en)
|
2019-07-26 |
2022-06-01 |
Amgen Inc. |
Anti-il13 antigen binding proteins
|
|
KR20220061977A
(ko)
|
2019-08-12 |
2022-05-13 |
퓨리노미아 바이오테크, 아이엔씨. |
Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물
|
|
WO2021064141A1
(en)
|
2019-10-02 |
2021-04-08 |
Tolremo Therapeutics Ag |
Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
|
|
US12478624B2
(en)
|
2019-10-02 |
2025-11-25 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
|
WO2021074418A1
(en)
|
2019-10-16 |
2021-04-22 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
|
WO2021074414A1
(en)
|
2019-10-16 |
2021-04-22 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
|
WO2021081440A2
(en)
|
2019-10-24 |
2021-04-29 |
Minotaur Therapeutics, Inc. |
Chimeric cytokine modified antibodies and methods of use thereof
|
|
CN114728905B
(zh)
|
2019-11-13 |
2025-08-01 |
基因泰克公司 |
治疗性化合物及使用方法
|
|
MX2022005914A
(es)
|
2019-11-19 |
2022-08-04 |
Modag Gmbh |
Compuestos novedosos para el diagnostico, tratamiento y prevencion de enfermedades asociadas con la agregacion de alfa-sinucleina.
|
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
|
WO2021183832A1
(en)
|
2020-03-11 |
2021-09-16 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
|
EP4161520A1
(en)
|
2020-06-05 |
2023-04-12 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Acvr1 (alk2) receptor inhibition to treat neurological diseases
|
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
|
CA3184062A1
(en)
|
2020-06-25 |
2021-12-30 |
Stefanie Fluckiger-Mangual |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
|
|
IL299344A
(en)
|
2020-06-25 |
2023-02-01 |
Tolremo Therapeutics Ag |
Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer
|
|
EP3939578A1
(en)
|
2020-07-13 |
2022-01-19 |
Novaremed Ltd. |
Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
EP4199968A1
(en)
|
2020-08-20 |
2023-06-28 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
|
EP3964497A1
(en)
|
2020-09-04 |
2022-03-09 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain
|
|
CA3200566A1
(en)
|
2020-10-02 |
2022-04-07 |
Genentech, Inc. |
Process for the preparation of biheteroaryl compounds and crystal forms thereof
|
|
WO2022079290A2
(en)
|
2020-10-16 |
2022-04-21 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Cullin ring ubiquitin ligase compounds and uses thereof
|
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
|
CA3209052A1
(en)
|
2021-02-19 |
2022-08-25 |
Rafael Cristian CASELLAS |
Single domain antibodies that neutralize sars-cov-2
|
|
US20250161471A1
(en)
|
2021-04-03 |
2025-05-22 |
Feng Tian |
Anti-her2 antibody-drug conjugates and uses thereof
|
|
BR112023020538A2
(pt)
|
2021-04-07 |
2024-01-23 |
Tolremo Therapeutics Ag |
Derivados heterocíclicos, composições farmacêuticas e seus usos no tratamento ou na melhoria de câncer
|
|
WO2022232321A1
(en)
|
2021-04-28 |
2022-11-03 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
|
US20230022990A1
(en)
|
2021-05-14 |
2023-01-26 |
Claris Biotherapeutics, Inc. |
Compositions of growth factor for the treatment of eye disease
|
|
WO2023028056A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
3-amino piperidyl sodium channel inhibitors
|
|
WO2023028077A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
Sodium channel inhibitors and methods of designing same
|
|
TW202340212A
(zh)
|
2021-11-24 |
2023-10-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
|
EP4436957A1
(en)
|
2021-11-24 |
2024-10-02 |
Genentech, Inc. |
Therapeutic indazole compounds and methods of use in the treatment of cancer
|
|
JP2025513492A
(ja)
|
2022-04-19 |
2025-04-24 |
フィリーラ ニュー ジーランド リミテッド |
脳銅障害の処置
|
|
WO2023203174A1
(en)
|
2022-04-20 |
2023-10-26 |
Proxygen Gmbh |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
|
JP2025515486A
(ja)
|
2022-04-29 |
2025-05-15 |
ピュリノミア バイオテック， インコーポレイテッド |
好酸球駆動性疾患及び障害を治療するための方法及び組成物
|
|
WO2025040546A1
(en)
|
2023-08-18 |
2025-02-27 |
Proxygen Gmbh |
Pyrazole compounds as cullin ring ubiquitin ligase compounds
|
|
WO2025104236A1
(en)
|
2023-11-15 |
2025-05-22 |
Proxygen Gmbh |
Pyrazole compounds as cullin ring ubiquitin ligase compounds
|